The platform achieves precision through a two-step process. First, focused ultrasound targets a specific organ for delivery. Second, the genetic payload itself contains regulatory elements like cell-specific promoters. This ensures that even though many cell types within the organ receive the payload, the therapeutic protein is only expressed in the desired cells.
Ken Greenberg envisions a future where administering genetic medicine resembles a procedure like radiology, not just a drug infusion. A physician will use real-time imaging to identify a target tissue and then precisely activate the intravenous drug only in that location. This paradigm shift redefines the clinical workflow and the role of the physician.
Unlike viral vectors that depend on biological interactions, Sonothera's ultrasound delivery is payload-agnostic. By using physical force to create temporary cell pores, it can deliver DNA, RNA, or CRISPR systems without redesigning the therapeutic itself. This fundamentally decouples the genetic cargo from the delivery mechanism, offering unprecedented flexibility.
Initial attempts to translate the technology to large animals failed, as standard acoustic profiles from academic literature were not efficient enough. The company overcame this "existential" challenge by developing proprietary acoustic profiles that yielded a 100-fold improvement in delivery, making the technology viable for human translation.
Sonothera is developing therapies for chronic administration (e.g., annually), avoiding the multi-million dollar price tags of single-dose gene therapies. This model dramatically reduces product cost and fits more easily into existing insurance reimbursement systems, which are built for recurring treatments rather than massive one-time payments.
Sonothera's method physically deposits genetic payloads into cells through transient pores, bypassing the endosomal pathways used by viruses and LNPs. This avoids triggering innate immune sensors like CGAS and STING. This “immune stealth” approach is key to the platform's favorable safety profile and its ability to be repeatedly administered.
Before targeting difficult tissues, Sonothera first focused on liver delivery of Factor VIII. This allowed them to directly compare their platform's safety and efficacy against established AAV and LNP benchmarks in a well-understood context. This strategic move built credibility and de-risked the technology before pursuing more novel applications.